Scholar Rock Holding Corporation (SRRK)
SRRK Stock Price Chart
Explore Scholar Rock Holding Corporation interactive price chart. Choose custom timeframes to analyze SRRK price movements and trends.
SRRK Company Profile
Discover essential business fundamentals and corporate details for Scholar Rock Holding Corporation (SRRK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 May 2018
Employees
128.00
Website
https://scholarrock.comCEO
David L. Hallal
Description
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Financial Timeline
Browse a chronological timeline of Scholar Rock Holding Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.84, while revenue estimate is $3.33m.
Earnings released on 7 May 2026
EPS came in at -$0.83 falling short of the estimated -$0.82 by -1.22%.
Earnings released on 3 Mar 2026
EPS came in at -$0.88 surpassing the estimated -$0.88 by +0.29%.
Earnings released on 14 Nov 2025
EPS came in at -$0.90 falling short of the estimated -$0.84 by -7.76%.
Earnings released on 6 Aug 2025
EPS came in at -$0.98 falling short of the estimated -$0.66 by -48.48%.
Earnings released on 14 May 2025
EPS came in at -$0.67 falling short of the estimated -$0.63 by -6.35%.
Earnings released on 27 Feb 2025
EPS came in at -$0.60 matching the estimated -$0.60.
Earnings released on 12 Nov 2024
EPS came in at -$0.66 falling short of the estimated -$0.58 by -13.77%.
Earnings released on 8 Aug 2024
EPS came in at -$0.60 surpassing the estimated -$0.61 by +1.64%.
Earnings released on 7 May 2024
EPS came in at -$0.59 falling short of the estimated -$0.51 by -15.69%.
Earnings released on 19 Mar 2024
EPS came in at -$0.50 falling short of the estimated -$0.49 by -2.04%, while revenue for the quarter reached $11.66m .
Earnings released on 7 Nov 2023
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 9 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$0.56 by +16.07%.
Earnings released on 9 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.
Earnings released on 7 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.58 by +20.69%, while revenue for the quarter reached $33.19m .
Earnings released on 14 Nov 2022
EPS came in at -$0.55 surpassing the estimated -$0.68 by +19.12%.
Earnings released on 8 Aug 2022
EPS came in at -$1.06 falling short of the estimated -$1.03 by -2.91%.
Earnings released on 16 May 2022
EPS came in at -$0.21 surpassing the estimated -$0.79 by +73.42%, while revenue for the quarter reached $33.19m , beating expectations by +49.98%.
Earnings released on 7 Mar 2022
EPS came in at -$0.97 surpassing the estimated -$1.04 by +6.73%, while revenue for the quarter reached $4.05m , missing expectations by -8.07%.
Earnings released on 9 Nov 2021
EPS came in at -$1.02 falling short of the estimated -$0.85 by -20.00%, while revenue for the quarter reached $5.46m , beating expectations by +17.76%.
Earnings released on 10 Aug 2021
EPS came in at -$0.84 falling short of the estimated -$0.78 by -7.69%, while revenue for the quarter reached $4.60m , meeting expectations.
SRRK Stock Performance
Access detailed SRRK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
